Counts and Characteristics of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor or Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Users with Type 2 Diabetes: A Descriptive Analysis

In this analysis, we examined counts of individuals with type 2 diabetes using dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors that had inflammatory bowel disease, ulcerative colitis, and Crohn’s disease in the Sentinel Distributed Database (SDD). We distributed this request to six Sentinel Data Partners on July 27, 2023. This analysis includes two reports:

• Report 1: Includes counts of individuals with type 2 diabetes using DPP-4 inhibitors or SGLT-2 inhibitors that had inflammatory bowel disease, ulcerative colitis, or Crohn’s disease. The study period includes data from March 29, 2013 to December 31, 2022.
• Report 2: Includes counts of individuals with type 2 diabetes using DPP-4 inhibitors or sulfonylureas that had inflammatory bowel disease, ulcerative colitis, or Crohn’s disease. The study period includes data from January 1, 2008 to December 31, 2022.